Robert Sambursky
Gründer bei Rapid Pathogen Screening, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Benjamin Scot Bergo | M | 47 |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.
RPS Diagnostics, Inc.
RPS Diagnostics, Inc. Medical SpecialtiesHealth Technology RPS Diagnostics, Inc. develops diagnostic solutions and medical instruments. Its product FebriDx is in-office test that uses a finger stick blood sample to help differentiate viral from bacterial acute respiratory infection. The company was founded by Robert P. Sambursky in 2004 and is headquartered in Sarasota, FL. | 5 Jahre |
Lawrence Mehren | M | 57 |
Lumos Diagnostics
Lumos Diagnostics Medical SpecialtiesHealth Technology Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA. | 3 Jahre |
Douglas Ward | M | - | 2 Jahre | |
Sam Lanyon | M | - |
Lumos Diagnostics
Lumos Diagnostics Medical SpecialtiesHealth Technology Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA.
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | - |
J. Scott Womble | M | - |
Rapid Pathogen Screening, Inc.
Rapid Pathogen Screening, Inc. Medical/Nursing ServicesHealth Services Rapid Pathogen Screening, Inc. is an emerging biotechnology company strategically focused on designing, developing, and delivering novel point-of-care tests for infectious diseases and inflammatory conditions as well as bio-terrorism and chemical nerve agent blood toxins. The firm’s products include AdenoPlus, InflammaDry, FebriDx. The company was founded by Robert P. Sambursky and Robert W. VanDine in 2004 and is headquartered in Sarasota, FL. | - |
Catherine Robson | F | - |
Lumos Diagnostics
Lumos Diagnostics Medical SpecialtiesHealth Technology Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA. | 3 Jahre |
Rhett M. Schiffman | M | - |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | - |
Bronwyn Le Grice | F | - |
Lumos Diagnostics
Lumos Diagnostics Medical SpecialtiesHealth Technology Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA. | 3 Jahre |
Tim Grinstead | M | - |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | 3 Jahre |
Dwight Moxie | M | 48 |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | 3 Jahre |
Tamir Meiri | M | - |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | - |
Sacha Dopheide | M | - |
Lumos Diagnostics
Lumos Diagnostics Medical SpecialtiesHealth Technology Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA. | - |
Daniel L. Sambursky | M | - |
Rapid Pathogen Screening, Inc.
Rapid Pathogen Screening, Inc. Medical/Nursing ServicesHealth Services Rapid Pathogen Screening, Inc. is an emerging biotechnology company strategically focused on designing, developing, and delivering novel point-of-care tests for infectious diseases and inflammatory conditions as well as bio-terrorism and chemical nerve agent blood toxins. The firm’s products include AdenoPlus, InflammaDry, FebriDx. The company was founded by Robert P. Sambursky and Robert W. VanDine in 2004 and is headquartered in Sarasota, FL. | - |
Tracy M. Valorie | F | 54 |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | 3 Jahre |
Tony Nguyen | M | - |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | - |
Chuck T. Saldarini | M | - |
Rapid Pathogen Screening, Inc.
Rapid Pathogen Screening, Inc. Medical/Nursing ServicesHealth Services Rapid Pathogen Screening, Inc. is an emerging biotechnology company strategically focused on designing, developing, and delivering novel point-of-care tests for infectious diseases and inflammatory conditions as well as bio-terrorism and chemical nerve agent blood toxins. The firm’s products include AdenoPlus, InflammaDry, FebriDx. The company was founded by Robert P. Sambursky and Robert W. VanDine in 2004 and is headquartered in Sarasota, FL. | - |
Eric D. Donnenfeld | M | 68 |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | 1 Jahre |
William Ryan | M | - |
Rapid Pathogen Screening, Inc.
Rapid Pathogen Screening, Inc. Medical/Nursing ServicesHealth Services Rapid Pathogen Screening, Inc. is an emerging biotechnology company strategically focused on designing, developing, and delivering novel point-of-care tests for infectious diseases and inflammatory conditions as well as bio-terrorism and chemical nerve agent blood toxins. The firm’s products include AdenoPlus, InflammaDry, FebriDx. The company was founded by Robert P. Sambursky and Robert W. VanDine in 2004 and is headquartered in Sarasota, FL. | 17 Jahre |
John Paul de Koning | M | 55 |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | 3 Jahre |
Caroline Popper | M | - |
Rapid Pathogen Screening, Inc.
Rapid Pathogen Screening, Inc. Medical/Nursing ServicesHealth Services Rapid Pathogen Screening, Inc. is an emerging biotechnology company strategically focused on designing, developing, and delivering novel point-of-care tests for infectious diseases and inflammatory conditions as well as bio-terrorism and chemical nerve agent blood toxins. The firm’s products include AdenoPlus, InflammaDry, FebriDx. The company was founded by Robert P. Sambursky and Robert W. VanDine in 2004 and is headquartered in Sarasota, FL. | - |
David Guyer | M | 64 |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | 3 Jahre |
Craig A. Mallitz | M | - |
RPS Diagnostics, Inc.
RPS Diagnostics, Inc. Medical SpecialtiesHealth Technology RPS Diagnostics, Inc. develops diagnostic solutions and medical instruments. Its product FebriDx is in-office test that uses a finger stick blood sample to help differentiate viral from bacterial acute respiratory infection. The company was founded by Robert P. Sambursky in 2004 and is headquartered in Sarasota, FL. | - |
James Lulo | M | - |
Rapid Pathogen Screening, Inc.
Rapid Pathogen Screening, Inc. Medical/Nursing ServicesHealth Services Rapid Pathogen Screening, Inc. is an emerging biotechnology company strategically focused on designing, developing, and delivering novel point-of-care tests for infectious diseases and inflammatory conditions as well as bio-terrorism and chemical nerve agent blood toxins. The firm’s products include AdenoPlus, InflammaDry, FebriDx. The company was founded by Robert P. Sambursky and Robert W. VanDine in 2004 and is headquartered in Sarasota, FL. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jennifer Christiansen | F | - | 1 Jahre | |
Robert VanDine | M | - |
Rapid Pathogen Screening, Inc.
Rapid Pathogen Screening, Inc. Medical/Nursing ServicesHealth Services Rapid Pathogen Screening, Inc. is an emerging biotechnology company strategically focused on designing, developing, and delivering novel point-of-care tests for infectious diseases and inflammatory conditions as well as bio-terrorism and chemical nerve agent blood toxins. The firm’s products include AdenoPlus, InflammaDry, FebriDx. The company was founded by Robert P. Sambursky and Robert W. VanDine in 2004 and is headquartered in Sarasota, FL. | - |
William Dodge Rueckert | M | 71 |
Rapid Pathogen Screening, Inc.
Rapid Pathogen Screening, Inc. Medical/Nursing ServicesHealth Services Rapid Pathogen Screening, Inc. is an emerging biotechnology company strategically focused on designing, developing, and delivering novel point-of-care tests for infectious diseases and inflammatory conditions as well as bio-terrorism and chemical nerve agent blood toxins. The firm’s products include AdenoPlus, InflammaDry, FebriDx. The company was founded by Robert P. Sambursky and Robert W. VanDine in 2004 and is headquartered in Sarasota, FL. | - |
Uma Mahesh Babu | M | - |
Rapid Pathogen Screening, Inc.
Rapid Pathogen Screening, Inc. Medical/Nursing ServicesHealth Services Rapid Pathogen Screening, Inc. is an emerging biotechnology company strategically focused on designing, developing, and delivering novel point-of-care tests for infectious diseases and inflammatory conditions as well as bio-terrorism and chemical nerve agent blood toxins. The firm’s products include AdenoPlus, InflammaDry, FebriDx. The company was founded by Robert P. Sambursky and Robert W. VanDine in 2004 and is headquartered in Sarasota, FL. | - |
Jill Thompson | F | - | 1 Jahre | |
Jeffrey Bishop | M | - | 3 Jahre | |
Kurt Phinney | M | - | 4 Jahre | |
Aaron Erlandson | M | - | 2 Jahre | |
Paul Kase | M | - |
Rapid Pathogen Screening, Inc.
Rapid Pathogen Screening, Inc. Medical/Nursing ServicesHealth Services Rapid Pathogen Screening, Inc. is an emerging biotechnology company strategically focused on designing, developing, and delivering novel point-of-care tests for infectious diseases and inflammatory conditions as well as bio-terrorism and chemical nerve agent blood toxins. The firm’s products include AdenoPlus, InflammaDry, FebriDx. The company was founded by Robert P. Sambursky and Robert W. VanDine in 2004 and is headquartered in Sarasota, FL. | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 26 | 81,25% |
Australien | 6 | 18,75% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Robert Sambursky
- Persönliches Netzwerk